Sumitomo Dainippon

Sumitomo merges U.S. biotechs to create oncology division
Sumitomo merges U.S. biotechs to create oncology division
Fierce Biotech
Sumitomo Dainippon
Tolero Pharmaceuticals
Boston Biomedical
oncology
M&A
Flag link:
For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials
For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials
Forbes
artificial intelligence
OCD
drug development
DSP-1181
Sumitomo Dainippon
Exscientia
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...
BioSpace
M&A
Roivant
Vivek Ramaswamy
Sumitomo Dainippon
Flag link:
Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M
Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M
Endpoints
Vivek Ramaswamy
Sumitomo Dainippon
Myovant
Flag link:
Roivant lines up $3B upfront in Sumitomo Dainippon deal
Roivant lines up $3B upfront in Sumitomo Dainippon deal
Fierce Biotech
M&A
Roivant
Sumitomo Dainippon
Flag link:
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Endpoints
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel
Flag link:
Japanese pharma snaps up cancer biotech Tolero
Japanese pharma snaps up cancer biotech Tolero
BioPharma Dive
Japan
Tolero Pharmaceuticals
M&A
Sumitomo Dainippon
Flag link:
Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
BioPharma Dive
orphan drugs
Sumitomo Dainippon
obeticholic acid
AbbVie
venetoclax
Actelion
Uptravi
Flag link:
Intercept's much-hyped NASH drug misses the mark in Phase II
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
Flag link: